SPNS3 and acute myeloid leukemia: Together, the evidence indicates that SPNS3 may be a potential target for AML therapy and that SPNS3-targeted therapy and that SPNS3-targeted therapy might improve the effect of venetoclax in combination with azacytidine treatment.